title: Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
abstract: A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT1) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.
authors: Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway. s.e.kjeldsen@medisin.uio.no
authors: Sverre E
authors: SE
authors: Kjeldsen
authors: Paulette A
authors: PA
authors: Lyle
authors: Jorge R
authors: JR
authors: Kizer
authors: Suzanne
authors: S
authors: Oparil
authors: Aud
authors: A
authors: Høieggen
authors: Ingrid
authors: I
authors: Os
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D019808:Losartan
references: JAMA. 2003 Jul 9;290(2):199-206
references: 12851274
references: J Hypertens. 2003 Aug;21(8):1563-74
references: 12872052
references: Circulation. 2003 Aug 12;108(6):684-90
references: 12885747
references: Clin Ther. 2001 Aug;23(8):1166-79
references: 11558856
references: Lancet. 2001 Sep 29;358(9287):1033-41
references: 11589932
references: Manag Care. 2000 Sep;9(9 Suppl):2-6
references: 11729417
references: Am J Hypertens. 2006 May;19(5):439-42
references: 16647610
references: Stroke. 2006 Jun;37(6):1583-633
references: 16675728
references: Eur Heart J. 2006 Jul;27(14):1651-6
references: 16603580
references: Clin Ther. 2006 Oct;28(10):1639-48
references: 17157119
references: Circulation. 2007 Feb 6;115(5):e69-171
references: 17194875
references: Curr Med Res Opin. 2007 Feb;23(2):259-70
references: 17288679
references: Curr Med Res Opin. 2007 Feb;23(2):443-57
references: 17288698
references: Hypertension. 2001 Dec 1;38(6):E28-32
references: 11751742
references: N Engl J Med. 2000 Jan 20;342(3):145-53
references: 10639539
references: Am J Hypertens. 2000 Jan;13(1 Pt 1):103-4
references: 10678279
references: Circulation. 2000 Apr 11;101(14):1653-9
references: 10758046
references: Cochrane Database Syst Rev. 2000;(2):CD000028
references: 10796688
references: Blood Press. 2001;10(4):190-2
references: 11800055
references: J Hypertens. 2002 Apr;20(4):779-84
references: 11910316
references: Lancet. 2002 Mar 23;359(9311):995-1003
references: 11937178
references: Circ Res. 2002 Apr 19;90(7):754-6
references: 11964366
references: Clin Ther. 2002 Jul;24(7):1049-61
references: 12182251
references: J Hypertens. 2002 Sep;20(9):1879-86
references: 12195132
references: Kidney Int. 2004 Mar;65(3):1041-9
references: 14871425
references: J Am Coll Cardiol. 2004 Mar 17;43(6):1047-55
references: 15028365
references: Expert Rev Cardiovasc Ther. 2003 May;1(1):43-50
references: 15030296
references: Lancet. 2004 Jun 19;363(9426):2022-31
references: 15207952
references: Clin Ther. 2004 May;26(5):631-48
references: 15220009
references: Lancet. 2004 Jul 31-Aug 6;364(9432):413; author reply 413-4
references: 15288732
references: J Hypertens. 2004 Sep;22(9):1805-11
references: 15311110
references: Circulation. 2004 Sep 14;110(11):1456-62
references: 15326072
references: Hypertension. 2004 Oct;44(4):398-404
references: 15326093
references: Clin Exp Hypertens. 1980;2(3-4):639-57
references: 6253243
references: J Cardiovasc Pharmacol. 1985;7 Suppl 1:S52-5
references: 2580177
references: Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):531-4
references: 3103761
references: Kidney Int. 1987 Mar;31(3):815-9
references: 3033389
references: J Clin Hypertens. 1987 Sep;3(3 Suppl):108S-113S
references: 3312505
references: Am J Cardiol. 1988 Jun 15;61(16):41H-45H
references: 3289350
references: J Cardiovasc Pharmacol. 1989 Feb;13(2):314-9
references: 2468963
references: Nephron. 1990;55 Suppl 1:70-2
references: 2345592
references: Stroke. 1991 Mar;22(3):312-8
references: 2003301
references: Stroke. 1992 Nov;23(11):1551-5
references: 1440701
references: J Hypertens Suppl. 1993 Apr;11(3):S37-42
references: 8315518
references: Hypertension. 1995 May;25(5):1042-4
references: 7737713
references: Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13
references: 9234823
references: Lancet. 1998 Oct;352 Suppl 3:SIII1-4
references: 9803954
references: Hypertension. 1998 Dec;32(6):989-97
references: 9856962
references: Lancet. 1999 Feb 20;353(9153):611-6
references: 10030325
references: J Clin Hypertens (Greenwich). 2004 Nov;6(11):614-20
references: 15538094
references: Hypertension. 2005 Jan;45(1):46-52
references: 15583076
references: Am J Cardiovasc Drugs. 2005;5(1):17-22
references: 15631534
references: J Am Coll Cardiol. 2005 Mar 1;45(5):705-11
references: 15734614
references: J Am Coll Cardiol. 2005 Mar 15;45(6):813-27
references: 15766813
references: Arch Intern Med. 2005 May 23;165(10):1147-52
references: 15911728
references: Stroke. 2005 Jun;36(6):1218-26
references: 15879332
references: Expert Opin Emerg Drugs. 2005 Nov;10(4):729-45
references: 16262560
references: Am J Hypertens. 2000 Apr;13(4 Pt 1):418-26
references: 10821345
references: Pharmacoeconomics. 2001;19(4):337-47
references: 11383751
references: JAMA. 2002 Sep 18;288(11):1388-95
references: 12234233
references: JAMA. 2002 Dec 18;288(23):2981-97
references: 12479763
references: J Hypertens. 2003 May;21(5):875-86
references: 12714861
references: JAMA. 2003 May 14;289(18):2363-9
references: 12746359
references: JAMA. 2003 May 21;289(19):2560-72
references: 12748199
references: JAMA. 2003 May 21;289(19):2534-44
references: 12759325
references: J Hypertens. 2003 Jun;21(6):1011-53
references: 12777938
references: BMJ. 2003 Jun 28;326(7404):1419
references: 12829553